Stocks News

LAST PRICE
375.3400
TODAY'S CHANGE (%)
Trending Down-0.9200 (-0.2445%)

Bid / Lots
374.2400/ 4
Ask / Lots
375.4700/ 1
Open / Previous Close
360.3700 / 376.2600
Day Range
Low 359.8850
High 375.4300
52 Week Range
Low 327.7250
High 550.7600
Volume
139,771
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease, from 12 hours ago by Dow Jones
  12 hours ago by Dow Jones
  Companies Mentioned: ARGX
  
  VYVGART and VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.
Apr 4, 2024
- European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading, from 11:06AM ET on Thursday Apr 04, 2024 by MT Newswires
  11:06AM ET on Thursday Apr 04, 2024 by MT Newswires
  Companies Mentioned: LYG, BUD, NVO, VOD, TRVG, VRNA, ARGX, NCNA, AMRN, BCYC, CALT, BPTS, TCBP, MTLS, BDRX, EDAP
  11:06 AM EDT, 04/04/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were trending higher Thursday morning, rising 0.69% to 1,386.14 on the S&P Europe Select ADR Index. From continental Europe, the gainers we...
Mar 27, 2024
- DJ arGEN-X Is Maintained at Buy by HC Wainwright & Co., from 11:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
  11:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
  Companies Mentioned: ARGX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ARGX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  March 27, 2024 11:00 ET (15:00 GMT)
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease, from 2:00AM ET on Wednesday Mar 27, 2024 by GlobeNewswire
  2:00AM ET on Wednesday Mar 27, 2024 by GlobeNewswire
  Companies Mentioned: ARGX
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease, from 2:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
  2:00AM ET on Wednesday Mar 27, 2024 by Dow Jones
  Companies Mentioned: ARGX
  
  argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease
  
  RHO study supports proof-of-concept in primary Sjogren's disease
  
  Decision informed by favorable safety profile and consistency across efficacy and biomarker measures

Yesterday
- Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing, from 21 hours ago by MT Newswires
  21 hours ago by MT Newswires
  Companies Mentioned: BMRN
Apr 8, 2024
- Sector Update: Health Care Stocks Flat to Higher Premarket Monday, from 9:28AM ET on Monday Apr 08, 2024 by MT Newswires
  9:28AM ET on Monday Apr 08, 2024 by MT Newswires
  Companies Mentioned: IBB, JNJ, NVO, XLV, ALNY, LEGN, CTLT
- Sector Update: Health Care, from 8:56AM ET on Monday Apr 08, 2024 by MT Newswires
  8:56AM ET on Monday Apr 08, 2024 by MT Newswires
  Companies Mentioned: ALNY
- RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating, from 7:44AM ET on Monday Apr 08, 2024 by MT Newswires
  7:44AM ET on Monday Apr 08, 2024 by MT Newswires
  Companies Mentioned: TECH
- Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY, from 7:22AM ET on Monday Apr 08, 2024 by Accesswire
  7:22AM ET on Monday Apr 08, 2024 by Accesswire
  Companies Mentioned: ALNY
- BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY, from 7:00AM ET on Monday Apr 08, 2024 by PR Newswire
  7:00AM ET on Monday Apr 08, 2024 by PR Newswire
  Companies Mentioned: TECH
- Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint, from 6:10AM ET on Monday Apr 08, 2024 by MT Newswires
  6:10AM ET on Monday Apr 08, 2024 by MT Newswires
  Companies Mentioned: ALNY
Apr 7, 2024
- Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension, from 8:00AM ET on Sunday Apr 07, 2024 by Business Wire
  8:00AM ET on Sunday Apr 07, 2024 by Business Wire
  Companies Mentioned: ALNY
Apr 3, 2024
- BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE, from 7:00AM ET on Wednesday Apr 03, 2024 by PR Newswire
  7:00AM ET on Wednesday Apr 03, 2024 by PR Newswire
  Companies Mentioned: TECH
Apr 1, 2024
- Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing, from 4:56PM ET on Monday Apr 01, 2024 by MT Newswires
  4:56PM ET on Monday Apr 01, 2024 by MT Newswires
  Companies Mentioned: BMRN

argenx SE
NASDAQ:ARGXUnited States

Search Criteria

Today

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease, from 12 hours ago by Dow Jones

Apr 4, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading, from 11:06AM ET on Thursday Apr 04, 2024 by MT Newswires

Mar 27, 2024

DJ arGEN-X Is Maintained at Buy by HC Wainwright & Co., from 11:00AM ET on Wednesday Mar 27, 2024 by Dow Jones

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease, from 2:00AM ET on Wednesday Mar 27, 2024 by GlobeNewswire

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease, from 2:00AM ET on Wednesday Mar 27, 2024 by Dow Jones

Peers Headlines

Yesterday

Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing, from 21 hours ago by MT Newswires

Apr 8, 2024

Sector Update: Health Care Stocks Flat to Higher Premarket Monday, from 9:28AM ET on Monday Apr 08, 2024 by MT Newswires

Sector Update: Health Care, from 8:56AM ET on Monday Apr 08, 2024 by MT Newswires

RBC Raises Price Target on Bio-Techne to $79 From $75, Keeps Sector Perform Rating, from 7:44AM ET on Monday Apr 08, 2024 by MT Newswires

Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY, from 7:22AM ET on Monday Apr 08, 2024 by Accesswire

BIO-TECHNE SURPASSES 10,000 PEER-REVIEWED PUBLICATIONS CITING RNAscope TECHNOLOGY, from 7:00AM ET on Monday Apr 08, 2024 by PR Newswire

Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint, from 6:10AM ET on Monday Apr 08, 2024 by MT Newswires

Apr 7, 2024

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension, from 8:00AM ET on Sunday Apr 07, 2024 by Business Wire

Apr 3, 2024

BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE, from 7:00AM ET on Wednesday Apr 03, 2024 by PR Newswire

Apr 1, 2024

Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing, from 4:56PM ET on Monday Apr 01, 2024 by MT Newswires